Wells Fargo lowered the firm’s price target on Nurix Therapeutics (NRIX) to $22 from $25 and keeps an Overweight rating on the shares. The firm believes management’s recent regulatory update on bexdeg and the forthcoming dose selection will provide investors clarity for the pivotal 3L+ trial. That coupled with read through from Kymera Therapeutics’ (KYMR) KT-621 Phase 1b update should offer upside for Nurix shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target lowered to $33 from $35 at Stifel
- 3 Best Stocks to Buy Now, 10/10/2025, According to Top Analysts
- Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer
- Nurix Therapeutics price target lowered to $32 from $35 at Piper Sandler
- Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating